These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 28148284)

  • 1. Rasagiline-induced severe recurrent hypoglycemia in a young woman without diabetes: a case report.
    Ibrahim FA; Rashid F; Hussain AA; Alawadi F; Bashier A
    J Med Case Rep; 2017 Feb; 11(1):29. PubMed ID: 28148284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial.
    Rascol O; Brooks DJ; Melamed E; Oertel W; Poewe W; Stocchi F; Tolosa E;
    Lancet; 2005 Mar 12-18; 365(9463):947-54. PubMed ID: 15766996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The monoamine oxidase type B inhibitor rasagiline in the treatment of Parkinson disease: is tyramine a challenge?
    Chen JJ; Wilkinson JR
    J Clin Pharmacol; 2012 May; 52(5):620-8. PubMed ID: 21628600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
    Chen JJ; Swope DM; Dashtipour K
    Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study.
    Parkinson Study Group
    Arch Neurol; 2005 Feb; 62(2):241-8. PubMed ID: 15710852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.
    Guay DR
    Am J Geriatr Pharmacother; 2006 Dec; 4(4):330-46. PubMed ID: 17296539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rasagiline meta-analysis: a spotlight on clinical safety and adverse events when treating Parkinson's disease.
    Solís-García del Pozo J; Mínguez-Mínguez S; de Groot PW; Jordán J
    Expert Opin Drug Saf; 2013 Jul; 12(4):479-86. PubMed ID: 23634791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline.
    deMarcaida JA; Schwid SR; White WB; Blindauer K; Fahn S; Kieburtz K; Stern M; Shoulson I; ;
    Mov Disord; 2006 Oct; 21(10):1716-21. PubMed ID: 16856145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic/pharmacodynamic evaluation of rasagiline mesylate for Parkinson's disease.
    Müller T
    Expert Opin Drug Metab Toxicol; 2014 Oct; 10(10):1423-32. PubMed ID: 25196265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Linezolid and Rasagiline - A culprit for serotonin syndrome.
    Hisham M; Sivakumar MN; Nandakumar V; Lakshmikanthcharan S
    Indian J Pharmacol; 2016; 48(1):91-2. PubMed ID: 26997732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rasagiline in Parkinson's disease.
    Chahine LM; Stern MB
    Int Rev Neurobiol; 2011; 100():151-68. PubMed ID: 21971007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tendon rupture as an adverse effect of rasagiline.
    Lefaucheur R; Fetter D; Gaillon G; Borden A; Maltête D
    Clin Neuropharmacol; 2014; 37(2):62. PubMed ID: 24614673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recurrent Impulse Control Disorder Associated with Rasagiline Treatment of Parkinson's Disease.
    Levy A; Lang AE
    Can J Neurol Sci; 2017 Jul; 44(4):447-448. PubMed ID: 28767029
    [No Abstract]   [Full Text] [Related]  

  • 14. Selegiline and rasagiline: twins or distant cousins?
    Knudsen Gerber DS
    Consult Pharm; 2011 Jan; 26(1):48-51. PubMed ID: 21224199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiac safety of rasagiline, a selective monoamine oxidase type B inhibitor for the treatment of Parkinson's disease: a thorough QT/QTc study.
    Mendzelevski B; Sprenger CR; Spiegelstein O; Rabinovich-Guilatt L
    Int J Clin Pharmacol Ther; 2014 Mar; 52(3):192-201. PubMed ID: 24447649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the safety and tolerability of rasagiline in the treatment of the early stages of Parkinson's disease.
    Viallet F; Pitel S; Lancrenon S; Blin O
    Curr Med Res Opin; 2013 Jan; 29(1):23-31. PubMed ID: 23176073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].
    Jost WH; Klasser M; Reichmann H
    Fortschr Neurol Psychiatr; 2008 Oct; 76(10):594-9. PubMed ID: 18833504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease.
    Parkinson Study Group
    Arch Neurol; 2004 Apr; 61(4):561-6. PubMed ID: 15096406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of rasagiline as adjunct therapy to levodopa on severity of OFF in Parkinson's disease.
    Stocchi F; Rabey JM
    Eur J Neurol; 2011 Dec; 18(12):1373-8. PubMed ID: 21895884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of rasagiline in elderly patients with Parkinson disease.
    Goetz CG; Schwid SR; Eberly SW; Oakes D; Shoulson I;
    Neurology; 2006 May; 66(9):1427-9. PubMed ID: 16682679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.